¼¼°èÀÇ ¸¸¼º Æó°íÇ÷¾Ð Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Chronic Pulmonary Hypertension Treatment Global Market Report 2025
»óǰÄÚµå : 1720758
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸¸¼º Æó°íÇ÷¾Ð Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 5.6%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 89¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÅõÀÚ Áõ°¡, ÀǾàǰ °³¹ß¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø È®´ë, ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ½Ä Áõ°¡, ¸¸¼º ³ú¼Õ»ó ¹ß»ý·ü »ó½Â µî¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ½Å¾à ¹× Ä¡·á¹ý °³¹ß, ±â¼ú ¹ßÀü, Á¦¾àȸ»ç, ¿¬±¸±â°ü, ÇコÄÉ¾î ±â°ü°úÀÇ Á¦ÈÞ, »õ·Î¿î ºÐÀÚ °æ·ÎÀÇ Æ¯Á¤, Á¤ºÎ ¹× ÇコÄÉ¾î ±â°üÀ¸·ÎºÎÅÍÀÇ ÅõÀÚ Áõ°¡, »õ·Î¿î Ä¡·á¹ý Çõ½Å µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü ÁúȯÀÇ ³ôÀº ºÎ´ãÀº ÇâÈÄ ¼ö³â°£ ¸¸¼º Æó°íÇ÷¾Ð Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÉÇ÷°ü Áúȯ¿¡´Â °ü»óµ¿¸Æ Áúȯ, ½ÉºÎÀü, ³úÁ¹Áß µî ½ÉÀå°ú Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ ÁúȯÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â °Ç°­ÇÏÁö ¸øÇÑ ½Ä»ýȰ, ¿îµ¿ ºÎÁ·, ´ã¹è »ç¿ë, °úµµÇÑ ¾ËÄÚ¿Ã ¼·Ãë, ºñ¸¸, °íÇ÷¾Ð, ´ç´¢º´, °í·ÉÈ­ µîÀÇ À§Çè ÀÎÀÚ¿Í °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. ¸¸¼º Æó°íÇ÷¾Ð Ä¡·á´Â Æóµ¿¸Æ¾ÐÀ» ³·Ãß°í ½É±â´ÉÀ» °³¼±ÇÏ¸ç ½ÉºÎÀüÀ̳ª °ü·Ã ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙ¿©ÁÜÀ¸·Î½á ½ÉÀåÇ÷°ü °Ç°­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 12¿ù È£ÁÖ Á¤ºÎ±â°üÀΠȣÁÖº¸°Çº¹Áö¿¬±¸¼Ò´Â °ü»óµ¿¸Æ¼º ½ÉÀåÁúȯ(CHD)À¸·Î ÀÎÇÑ ÀÇ»ç ÀÎÁ¤ »ç¸ÁÀÚ ¼ö°¡ 2021³â 1¸¸ 4,100¸í¿¡¼­ 2022³â 1¸¸ 4,900¸íÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ã Áõ°¡°¡ ¸¸¼º Æó°íÇ÷¾Ð Ä¡·á ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸¸¼º Æó°íÇ÷¾Ð Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ÇÇÇÏ ÁÖ»ç¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» ¼±È£ÇÏ¿© ȯÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ ³ôÀ̰í, ÆíÀǼºÀ» Çâ»ó½Ã۸ç,º¸´Ù ÃÊÁ¡À» ¸ÂÃá Ä¡·á ¿É¼ÇÀ» Á¦°øÇϱâ À§ÇØ ÇÇÇÏÁÖ»ç µî Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. ÇÇÇÏÁÖ»ç´Â ÇÇÇÏ¿¡ Áö¼ÓÀûÀ¸·Î ¾àÁ¦¸¦ Åõ¿©ÇÔÀ¸·Î½á Æóµ¿¸Æ¾ÐÀ» È¿°úÀûÀ¸·Î ÀúÇϽÃŰ°í Æó°íÇ÷¾Ð ȯÀÚÀÇ Ç÷·ù¸¦ °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 3¿ù ¹Ì±¹ Á¦¾àȸ»çÀÎ Merck & Co Inc.´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ Winrevair(sotatercept-csrk)¸¦ ½ÂÀÎÇß´Ù°í ¹ßÇ¥ÇØ Æóµ¿¸Æ¼º Æó°íÇ÷¾Ð(PAH) Ä¡·á¿¡ Å« Áøº¸¸¦ °¡Á®¿Ô½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº PAH¿¡ ´ëÇÑ È¹±âÀûÀÎ ¼±ÅÃÁö·Î¼­ µÎµå·¯Áø È¿°ú¸¦ °¡Á®¿É´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­´Â WHO ±â´É ºÐ·ù¿¡¼­ À§¾à±º¿¡¼­´Â 14%¿´´ø ¹Ý¸é, Winrevair¿¡¼­´Â 29%ÀÇ È¯ÀÚ¿¡¼­ °³¼±ÀÌ ÀÎÁ¤µÇ¾î ȯÀÚÀÇ QOLÀÇ ÀüüÀûÀÎ Çâ»óÀ¸·Î À̾îÁ³½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Chronic pulmonary hypertension (PH) treatment involves managing elevated blood pressure in the lungs to enhance heart function and overall quality of life. This includes medications to lower pressure, oxygen therapy, and diuretics to alleviate symptoms. Advanced treatments may involve pulmonary rehabilitation, lifestyle modifications, and, if necessary, medical procedures. In severe cases, surgical interventions might be considered.

The primary drug categories for chronic pulmonary hypertension include endothelin receptor antagonists (ERAs), phosphodiesterase (PDE-5) inhibitors, prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. ERAs work by blocking endothelin to manage pulmonary hypertension and enhance quality of life. These medications are available in different forms, including oral, intravenous, subcutaneous, and inhalational routes, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic pulmonary hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides chronic pulmonary hypertension treatment market statistics, including the chronic pulmonary hypertension treatment industry global market size, regional shares, competitors with the chronic pulmonary hypertension treatment market share, detailed chronic pulmonary hypertension treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pulmonary hypertension treatment industry. This chronic pulmonary hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic pulmonary hypertension treatment market size has grown strongly in recent years. It will grow from $6.82 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be credited to the rising prevalence of chronic pulmonary hypertension, an increase in drug approvals, favorable reimbursement policies, growing healthcare expenditure, and an aging population.

The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $8.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be credited to the rising demand for effective treatments, increasing investments, greater government support for drug development, growing demand for advanced therapeutics, heightened awareness, and the rising incidence of chronic brain injuries. Key trends include the development of new drugs and therapies, technological advancements, collaborations with pharmaceutical companies, research institutions, and healthcare organizations, identification of new molecular pathways, increased investments from governments and healthcare organizations, and the innovation of new therapies.

The high burden of cardiovascular diseases is expected to drive the growth of the chronic pulmonary hypertension treatment market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increasing prevalence of these diseases is linked to risk factors such as unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Chronic pulmonary hypertension treatment plays a crucial role in cardiovascular health by lowering pulmonary artery pressure, improving heart function, and reducing the risk of heart failure and related complications. For example, in December 2023, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. This rising burden of cardiovascular diseases is contributing to the expansion of the chronic pulmonary hypertension treatment market.

Leading companies in the chronic pulmonary hypertension treatment market are prioritizing innovative solutions, such as subcutaneous injections, to enhance patient compliance, improve convenience, and offer more targeted treatment options. Subcutaneous injection delivers continuous medication under the skin, effectively lowering pulmonary artery pressure and improving blood flow in patients with pulmonary hypertension. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), marking a major advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy provides significant benefits, setting it apart as a groundbreaking option for PAH. Clinical trials showed that Winrevair improved WHO functional class in 29% of patients, compared to 14% in the placebo group, leading to overall enhancements in patients' quality of life.

In October 2024, Liquidia Corporation, a US-based biopharmaceutical company, partnered with Pharmosa Biopharm to accelerate the development and commercialization of L606. This collaboration aims to advance L606, an inhaled treprostinil therapy, to enhance treatment options for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharmosa Biopharm, a Taiwan-based biotechnology company, specializes in the research, development, and commercialization of pharmaceuticals and medical devices.

Major players in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, and Liquidia Technologies.

North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in chronic pulmonary hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pulmonary hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic pulmonary hypertension treatment market consists of revenues earned by entities by providing services such as pharmacological treatment services, cardiopulmonary rehabilitation, telemedicine and remote patient monitoring, oxygen therapy, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pulmonary hypertension treatment market also includes sales of calcium channel blockers, pulmonary artery pressure monitoring systems, inhalation devices, and oxygen therapy equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Pulmonary Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic pulmonary hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic pulmonary hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic pulmonary hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Pulmonary Hypertension Treatment Market Characteristics

3. Chronic Pulmonary Hypertension Treatment Market Trends And Strategies

4. Chronic Pulmonary Hypertension Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Pulmonary Hypertension Treatment Growth Analysis And Strategic Analysis Framework

6. Chronic Pulmonary Hypertension Treatment Market Segmentation

7. Chronic Pulmonary Hypertension Treatment Market Regional And Country Analysis

8. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market

9. China Chronic Pulmonary Hypertension Treatment Market

10. India Chronic Pulmonary Hypertension Treatment Market

11. Japan Chronic Pulmonary Hypertension Treatment Market

12. Australia Chronic Pulmonary Hypertension Treatment Market

13. Indonesia Chronic Pulmonary Hypertension Treatment Market

14. South Korea Chronic Pulmonary Hypertension Treatment Market

15. Western Europe Chronic Pulmonary Hypertension Treatment Market

16. UK Chronic Pulmonary Hypertension Treatment Market

17. Germany Chronic Pulmonary Hypertension Treatment Market

18. France Chronic Pulmonary Hypertension Treatment Market

19. Italy Chronic Pulmonary Hypertension Treatment Market

20. Spain Chronic Pulmonary Hypertension Treatment Market

21. Eastern Europe Chronic Pulmonary Hypertension Treatment Market

22. Russia Chronic Pulmonary Hypertension Treatment Market

23. North America Chronic Pulmonary Hypertension Treatment Market

24. USA Chronic Pulmonary Hypertension Treatment Market

25. Canada Chronic Pulmonary Hypertension Treatment Market

26. South America Chronic Pulmonary Hypertension Treatment Market

27. Brazil Chronic Pulmonary Hypertension Treatment Market

28. Middle East Chronic Pulmonary Hypertension Treatment Market

29. Africa Chronic Pulmonary Hypertension Treatment Market

30. Chronic Pulmonary Hypertension Treatment Market Competitive Landscape And Company Profiles

31. Chronic Pulmonary Hypertension Treatment Market Other Major And Innovative Companies

32. Global Chronic Pulmonary Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Pulmonary Hypertension Treatment Market

34. Recent Developments In The Chronic Pulmonary Hypertension Treatment Market

35. Chronic Pulmonary Hypertension Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â